Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 27 entries
View as:

Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD4205 in Healthy Adult Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT04225208 Org: User:
Start: 01/06/20 End: 03/02/20 Due: 03/02/21

AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)

Phase: N/A Priority: Normal
NCT ID: NCT06511869 Org: User:
Start: 03/17/22 End: 03/31/26 Due: 03/31/27

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer with EGFR or HER2 Mutation (WU-KONG1)

Phase: N/A Priority: Normal
NCT ID: NCT03974022 Org: User:
Start: 07/09/19 End: 07/31/25 Due: 07/31/26

Pharmacokinetic and Mass Balance Study of Oral-Administrated [14C]-DZD9008 in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05159895 Org: User:
Start: 09/24/21 End: 03/30/22 Due: 03/30/23

Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)

Phase: N/A Priority: Normal
NCT ID: NCT05926180 Org: User:
Start: 07/31/23 End: 09/28/24 Due: 09/28/25

AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)

Phase: N/A Priority: Normal
NCT ID: NCT06511895 Org: User:
Start: 05/31/22 End: 12/31/26 Due: 12/31/27

A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)

Phase: N/A Priority: Normal
NCT ID: NCT06295432 Org: User:
Start: 06/01/23 End: 06/30/25 Due: 06/30/26

Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Meal on PK of DZD9008 in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT04909242 Org: User:
Start: 04/21/21 End: 02/07/22 Due: 02/07/23

DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

Phase: N/A Priority: Normal
NCT ID: NCT06276283 Org: User:
Start: 02/15/23 End: 02/28/26 Due: 02/28/27

Drug-drug Interactions Between AZD4205 and Itraconazole/Carbamazepine

Phase: N/A Priority: Normal
NCT ID: NCT05486949 Org: User:
Start: 07/27/22 End: 10/11/22 Due: 10/11/23

A Study of DZD2269 in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT04932005 Org: User:
Start: 06/29/21 End: 04/12/22 Due: 04/12/23

A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

Phase: N/A Priority: Normal
NCT ID: NCT06905197 Org: User:
Start: 06/30/25 End: 12/31/28 Due: 12/31/29

A Study of AZD4205 in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03728023 Org: User:
Start: 11/12/18 End: 08/20/19 Due: 08/20/20

Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03450330 Org: User:
Start: 04/16/18 End: 01/10/20 Due: 01/10/21

Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)

Phase: N/A Priority: Normal
NCT ID: NCT05712902 Org: User:
Start: 07/19/21 End: 12/31/25 Due: 12/31/26

DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05824585 Org: User:
Start: 05/15/23 End: 10/30/27 Due: 10/30/28

DZD9008 PK Study in Hepatic Impairment Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06084104 Org: User:
Start: 10/17/23 End: 10/23/24 Due: 10/23/25

Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine

Phase: N/A Priority: Normal
NCT ID: NCT05418582 Org: User:
Start: 01/25/22 End: 12/08/22 Due: 12/08/23

Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)

Phase: N/A Priority: Normal
NCT ID: NCT04148742 Org: User:
Start: 08/31/21 End: 07/31/23 Due: 07/31/24

Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)

Phase: N/A Priority: Normal
NCT ID: NCT06813365 Org: User:
Start: 06/12/24 End: 06/30/27 Due: 06/30/28

A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)

Phase: N/A Priority: Normal
NCT ID: NCT05844956 Org: User:
Start: 06/01/22 End: 02/29/24 Due: 02/28/25

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Phase: N/A Priority: Normal
NCT ID: NCT05668988 Org: User:
Start: 12/13/22 End: 10/31/27 Due: 10/31/28

DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04509596 Org: User:
Start: 09/21/20 End: 07/07/22 Due: 07/07/23

Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)

Phase: N/A Priority: Normal
NCT ID: NCT04105010 Org: User:
Start: 09/10/19 End: 02/22/24 Due: 02/22/25

DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)

Phase: N/A Priority: Normal
NCT ID: NCT06539195 Org: User:
Start: 03/13/24 End: 04/30/28 Due: 04/30/29